Cancer Patients and Researchers Question FDA-Approved Drug Dosages
Source Summary
Northwestern University economist Chuck Manski, who studies decision-making under uncertainty, faced a decision about continuing an immunotherapy treatment that was causing severe illness. Patients and researchers are challenging whether FDA-approved cancer drug dosages are appropriate, raising questions about the balance between efficacy and patient safety.
Why it matters
Standard FDA-approved dosages may not be optimal for all patients, and patient experiences with severe side effects are prompting a reassessment of cancer treatment protocols.
